Isis Pharmaceuticals, Ciba-Geigy Ltd. deal

The companies broadened their antisense program to include ISIS 3521, an anticancer compound that is an antisense inhibitor of protein kinase C ( PKC)-a. The companies anticipate filing an IND on the compound by the end of the year.

As amended, the collaboration will include research to discover and develop additional therapeutic compounds that target isotypes of the multi-gene family PKC. Isotypes of PKC are implicated in cancer and inflammation. ...